64results about How to "Activity has no effect" patented technology

A medium-and low-temp multi-element catalyst for denitrifying fume, that is, using NH4 for selective catalytic reduction (SCR) to Nox is composed of the oxide of Mn as active component, TiO2 as carrier, and the co-catalyst chosen from the oxides of valence-varied Fe, Cu, V, Ce and Cr. Its advantages are high catalytic activity and high resistance to SO2 and H2O poisoning.

The invention relates to a titanium-based multi-metal oxide catalyst for removing diesel engine NOx by NH3-SCR in a wide temperature window, belonging to the technical field of exhaust contaminant control on diesel engine tail gas. The catalyst uses nano TiO2 as a carrier, uses metal oxides V2O5, CeO2, MnO2 and Fe2O3 as main active components, and uses WO3 and MoO3 as catalyst promoter components, wherein the contents of the main active component in the catalyst respectively are as follows in percentage by weight: 48-84% of TiO2, 1-3% of V2O5, 5-15% of MnO2, 1-5% of CeO2, 1-5% of Fe2O3, 3-9% of WO3 and 5-15% of MoO3. The preparation process of the catalyst comprises the following steps: pre-activating the TiO2; and determining charge numbers of the metal oxide main active components and the catalyst promoters, and charging the metal oxide main active components and the catalyst promoters. By replacing high poisonous V oxides with Ce, Mn and Fe oxides, the invention reduces environmental hazard of the catalyst, greatly improves the low-temperature activation and the high-temperature selectivity, and effectively decreases NOx in the wide temperature window of 100-550 DEG C. The catalyst has high sulfur poisoning resistance and water poisoning resistance, and is suitable for high-sulfur diesel fuel and urban road conditions in China.

The invention discloses a hyperglycosylated human coagulation factor VIII (FVIII) fusion protein and a preparation method and application thereof. The fusion protein successively contains human FVIII, a soft peptide connector, at least one human chorionic gonadotropin betasubunitcarboxyl terminal peptide rigid unit and prolonged half-life period portion (preferably ahumanIgG Fc variant) from an end N to an end C. The fusion protein has biological activity similar to that of recombinant FVIII and prolonged in-vivo activity half-life period, thereby improving the pharmacokinetics and drug efficacy.

The invention relates to a catalyst for low-temperature denitration of power-plant flue gas by selective catalytic reduction (SCR) and a preparation method thereof. Tungsten-doped titanium pigment synthesized by metatitanic acid serous fluid and ammonium paratungstate oxalic acid solution which are manufactured in China is used as the carrier of the catalyst to largely reduce the cost. The catalyst uses cerium oxides as main active components and titanium dioxides as carriers, two or more of oxides of valence-variable metal manganese, iron, vanadium or chromium are added as catalyst promoters,and additionally, silicon oxides are added to increase the strength of the catalyst. The denitration efficiency of the catalyst prepared by the method reaches more than 90% at 180 DEG C; at 200 DEG C, the activity approximates to 100%, and the catalyst has favorable capability for resisting SO2 poisoning; and at the reaction temperature of 200 DEG C, the added SO2 hardly has effect on the activity of the catalyst.

The invention discloses a constructing method of stem cell breeding and differentiation microenvironment in vitro in the stem cell tissue engineering domain, which comprises the following steps: adopting sodium alginate and polylysine as material to prepare APA microencapsulation ES cell; adding microencapsulation ES cell in the ES growing culture medium; stewing at 37 Deg C in the culture box with 5% CO2; changing culture medium every 2-3d to obtain the product. The invention simplifies the operation to generate high-density and large scale augmentation, which can inhibit or delay the oriental differentiation for ES cell.

The invention belongs to the technical field of medicines, and in particular relates to a compound taking thieno-pyrimidone as mother nuclide or a salt thereof, a preparation method and a combination of the compound and application of the compound used as a DPP-IV (dipeptidyl peptidase) inhibitor in preventing or treating diseases benefiting from the DPP-IV inhibition. The compound provided by the invention has the advantages that the preparation process is simple, the raw material is easily available, the compound is suitable for large-scale production, and in-vitro experiment verifies that the compound has good selective inhibition action on the DPP-IV, and hardly has any influence on the activities of DPP-VIII and DPP-IX while effectively inhibiting the activity of the DDP-IV, thereby predicting that the medicine prepared from the compound has very low toxicity and an outstanding advantage.

The invention belongs to the technical field of medicines, relates to a high-efficient DPP (dipeptidyl peptidase)-IV inhibitor, and specifically relates to a compound taking uracil as a mother nucleus, or a salt thereof, a preparation method, a composition and an application of the compound as the DPP-IV inhibitor in prevention or treatment of diseases which benefit from DPP-IV inhibition. The compound disclosed by the invention has a very good selective inhibition effect against DPP-IV and has very low cardiotoxicity, thereby being a DPP-IV inhibitor type medicament with great prospects.

The invention discloses a titanium-based nano-composite metal oxide catalyst and a preparation method thereof, belonging to the technical field of control on exhaust contaminants in diesel engine tail gas. In the invention, the titanium-based nano-composite metal oxide catalyst is prepared by taking TiO2 as a carrier and taking metal oxides (VOx, MnOx and CeOx) as active components by adopting a self-propagating high-temperature synthesis (SHS) method, wherein the molar percentage of the TiO2 is 80-95%, the molar percentage of the VOx is 2-20%, the molar percentage of the MnOx is 2-10%, and the molar percentage of the CeOx is 2-10%. The preparation method of the titanium-based nano-composite metal oxide catalyst comprises the following steps of: preparing a TiO(NO3)2 precursor solution; determining the loads of the active components of the metal oxides; preparing a precursor solution of the active components of the metal oxides; and preparing the catalyst by SHS. The catalyst prepared by the method disclosed by the invention has the advantages of large specific surface area, large pore volume, proper pore size distribution and low degree of crystallization, all active species are highly dispersed and are interactive, the catalyst has higher NOx removing rate and N2 selectivity in a wide temperature window at 100-450 DEG C, and the catalyst has strong anti-sulfur and anti-water poisoning performance and is suitable for treating NOx in diesel engine tail gas of automobiles and ships.

The invention relates to a sulfur-resistant and water-proof low temperature catalyst for selective catalytic reduction (SCR) of nitrogen oxides by NH3 in flue gas denitration and a preparation method thereof. The catalyst adopts oxides of iron and manganese as active components, takes nano-titanium dioxide as the carrier, and employs the oxides of two or over two of the valence changing metal cerium, copper, vanadium and chromium as catalyst assistants. The best activity SCR catalyst prepared by the method can have SCR activity up to 94% under the operation conditions of CNO=CNH3=0.4%, CO2=2.5%, space velocity=9000h<-1> and a reaction temperature of 130DEG C, and activity close to 100% at 150DEG C, and has very good anti-SO2 and H2O poisoning capacity. Uner a reaction temperature of 150DEG C, the individual adding of SO2 almost has no influence to the activity, and after individual adding of 10.2% of H2O, the conversion rate of NO can maintain at about 85% for a long time, even under the circumstance of coexistence of about 1000*10<-6> of SO2 and 3.5% of H2O poisoning components, the activity can maintain at about 83% for a long time. Therefore, the SCR sulfur-resistant and water-proof low temperature catalyst has good industrial application prospects.

The invention belongs to the biological technical field and relates to a method of screening a tumor multidrug resistance reversal agent. In the method, a promoter specific sequence of a multidrug resistance (MDR1) gene is cloned and regrouped into a firefly luciferase report gene vector promotor sequence, therefore, an MDR1 report gene vector is constructed. The constructed vector and the sea pansy luciferase report gene vector are cotransfected into a sensitive and drug resistant colon cancer cell line. The activities of fireflies and the luciferase are detected simultaneously to reflect the promotor transcription activity of a MDRI gene promoter. Therefore, the method of screening the tumor multidrug resistance reversal agent in a targeted way is constructed. The method has perfect application prospect in screening tumor multidrug resistance reversal agents, researching the mechanism of the tumor multidrug resistance reversal agents and mechanisms of chemotherapeutic drugs inducing humor cells to generate drug resistance, etc.

The invention discloses a catalyst for removing NOx of a diesel engine. The catalyst for removing the NOx of the diesel engine is characterized in that the catalyst is a multi-element metal oxide, and comprises TiO2 which serves as a carrier component, CeO2 and CuO which serve as main active ingredients, and WO3 which serves as a catalyst promoter component; the mass percentage of various components are respectively as follows: 55 to 65 percent of TiO2, 23 to 28 percent of CeO2, 3 to 5 percent of CuO, and 10 to 13 percent of WO3, and the sum of the mass percentage is 100 percent; the catalyst can be used in a catalysis process of NH3-SCR in a wide temperature window; the multi-element metal oxide catalyst provided by the invention has a relatively wide active temperature window, and particularly the removal efficiency of the NH3-SCR to NOx is improved under the working conditions of low exhaust temperature (100 to 250 DEG C) of the diesel engine, so that the purpose of greatly reducing the NOx in a wide exhaust temperature window of the diesel engine at 100 to 450 DEG C is achieved; therefore, the catalyst is particularly suitable for the traffic conditions of urban roads of China.

The invention relates to a method and a device for joint denitrifying by denitrification and anaerobic ammonia oxidation embedding particles, and belongs to the field of sewage. The method comprises the following steps of respectively embedding a WPU (water-borne polyurethane) material by separated denitrification bacteria and anaerobic ammonia oxidation bacteria, putting the denitrification embedding particles into a flow-separated ball, putting anaerobic ammonia oxidation embedding particles into a Pall ring or into water in a floating state, and setting the denitrification embedding particles and the anaerobic ammonia oxidation embedding particles into an incomplete mixing state. The device comprises a water bath constant-temperature system, a sealing device, the flow-separated ball, the Pall ring and the like. The method and the device have the advantages that after embedding of the denitrification bacteria and anaerobic ammonia oxidation bacteria, the influence to the activity is avoided, the amounts of the denitrification bacteria and the anaerobic ammonia oxidation bacteria in the system are increased, the loss of bacteria amounts is reduced, the problems of slow growth of the anaerobic ammonia oxidation bacteria and stricter growth environment requirement in an anaerobic ammonia oxidation technology are solved, and the denitrifying efficiency of the system is improved by combining a nitrifying mode; the two types of embedding are set into the incomplete mixing state in the device, and respective feeding ratios can be flexibly adjusted according to the water quality.

The invention relates to the field of biology, and in particular to a method for extracting collagen from giant salamander. The method comprises the following steps: sterilization treatment, acid leaching, water washing, alkaline leaching, secondary water washing, salt leaching, enzymolysis and purifying. According to the method disclosed by the invention, the collagen is extracted by utilizing a mixture of the skin, the muscle and the bones of the giant salamander as a raw material, and the resource of the giant salamander is fully utilized; through the operation steps of sterilization treatment, acid leaching, water washing, alkaline leaching, secondary water washing, salt leaching, enzymolysis and purifying, the extracting rate and the purity of giant salamander collagen are effectively increased, determination shows that the extracting rate is up to 75.2 percent and the purity is up to 97.8 percent, the demands on the collagen and the pursuit to quality of a current market are effectively met, and the market application value of the collagen is increased.

The invention discloses an exenatide modified compound, a use of the exenatide modified compound in preparation of a medicine which serves as a GLP-1 receptor stimulant, a use of the exenatide modified compound in preparation of medicines used for preventing and / or curing diseases and / or symptoms relevant to low GLP-1 receptor activity, a use of the exenatide modified compound in preparation of medicines used for diseases and / or symptoms relevant to carbohydrate metabolism, a use of the exenatide modified compound in preparation of medicines used for diabetes, a use of the exenatide modified compound in preparation of medicines used for fatty liver, and a use of the exenatide modified compound in preparation of medicines used for weight losing.

The invention belongs to the technical field of medicines, and particularly relates to compounds which are shown as a general formula I and in which pyrrolopyrimidone is taken as a parent nucleus or salts thereof, a method for preparing the compounds, a composition, and use of the compounds as dipeptidyl peptidase-IV (DPP-IV) inhibitors in the prevention or treatment of diseases which benefit from DPP-IV inhibition. The preparation process for the compounds is simple, raw materials are readily available, and the method is suitable for industrialized production; through in-vitro experiments, the compounds have a good effect of selectively inhibiting DPP-IV, and almost do not affect the activities of DPP-VIII and DPP-IX when the activity of the DPP-IV is effectively inhibited; and the compounds are expected to have low toxicity after being developed into medicines, and have outstanding advantages.

The invention discloses mTAT-hEGF-kCD47 fusion protein. mTAT, kCD47 and hEGF are subjected to fusion expression, a complete genome sequence of mTAT-hEGF-kCD47 is designed, after artificial synthesis is conducted, the complete genome sequence of the mTAT-hEGF-kCD47 is connected with the interior of a pTrcHisB expression vector, an mTAT-hEGF-kCD47 recombinant expression plasmid vector is constructedsuccessfully, through expression and purification, the mTAT-hEGF-kCD47 fusion protein with biological activity is obtained, and the mTAT-hEGF-kCD47 fusion protein has the advantages of being low in cost, high in activity and long in action time. According to the mTAT-hEGF-kCD47 fusion protein, not only are original penetrating power of TAT and the action of CD47 of inhibiting nonspecific immune response reserved, but also the activity of the foreign protein hEGF is almost not affected, so that the mTAT-hEGF-kCD47 fusion protein has wide prospects in preparing medicines and make-ups for promoting epidermis proliferation.

The invention belongs to the field of tumor treatment, and discloses an anti-EGFR / PD-1 bispecific antibody, a preparation method and an application in tumor resistance. More specifically, a single-chain variable fragment scFv and an immunoglobulin antibody IgG are connected through a peptide joint L2 to obtain the bispecific antibody with a structure and a function similar to those of a full antibody; the bispecific antibody has the functions of targeting a tumor surface antigen EGFR and activating tumor immunity, and can effectively exert the ADCC function of an Fc segment of the antibody. Compared with a monoclonal antibody, the molecule has an obvious synergistic effect, and the anti-tumor effect of the molecule is superior to that of antibody combination.

The invention relates to a compound shown in a formula I or a salt, a preparation and a composition thereof and application of the compound serving as a dipeptidyl peptidase-IV (DPP-IV) inhibitor to the prevention or treatment of diseases which benefit from DPP-IV inhibition. The compound has a simple preparation process, is readily available in raw materials and is suitable for large-scale industrial production; and in-vitro experiments verify that the compound has a good selective inhibition effect on the DPP-IV, and influences the activity of DPP-VIII and DPP-IX scarcely while the activity of the DPP-IV is inhibited effectively, so after the compound is developed to form medicaments, the toxicity is far lower than that of a control medicament, and the compound has prominent advantages.

The invention discloses a C-triaryl glucoside compound with the structure shown in the formula I as shown in the description, or an optical isomer thereof, or pharmaceutically acceptable salt, co-crystallization composite, hydrate, solvate or prodrug molecule thereof. The compound disclosed by the invention has a very good selective inhibition effect on SGLT-2, has an obvious promotion effect on releasing of animal urine sugar, can effectively reduce blood glucose and meanwhile cannot result in the risks of weight increase, hypoglycemia and the like. The compound disclosed by the invention haslittle influence on the activity of SGLT-1 while effectively inhibiting the activity of SGLT-2, can be expected that the toxicity is low when being developed into drugs, and has obvious medication advantage.

The invention belongs to the technical field of medicines, relates to a preparation method of a high-efficient DPP (dipeptidyl peptidase)-IV inhibitor, and specifically relates to a compound taking uracil as a mother nucleus, or a pharmaceutically acceptable salt thereof, a preparation method, a composition and an application of the compound as the DPP-IV inhibitor in prevention or treatment of diseases which benefit from DPP-IV inhibition. The compound disclosed by the invention has a very good selective inhibition effect against DPP-IV and has very low cardiotoxicity, thereby being a DPP-IV inhibitor type medicament with great prospects.

The invention discloses a titanium-based nano-composite metal oxide catalyst and a preparation method thereof, belonging to the technical field of control on exhaust contaminants in diesel engine tail gas. In the invention, the titanium-based nano-composite metal oxide catalyst is prepared by taking TiO2 as a carrier and taking metal oxides (VOx, MnOx and CeOx) as active components by adopting a self-propagating high-temperature synthesis (SHS) method, wherein the molar percentage of the TiO2 is 80-95%, the molar percentage of the VOx is 2-20%, the molar percentage of the MnOx is 2-10%, and the molar percentage of the CeOx is 2-10%. The preparation method of the titanium-based nano-composite metal oxide catalyst comprises the following steps of: preparing a TiO(NO3)2 precursor solution; determining the loads of the active components of the metal oxides; preparing a precursor solution of the active components of the metal oxides; and preparing the catalyst by SHS. The catalyst preparedby the method disclosed by the invention has the advantages of large specific surface area, large pore volume, proper pore size distribution and low degree of crystallization, all active species are highly dispersed and are interactive, the catalyst has higher NOx removing rate and N2 selectivity in a wide temperature window at 100-450 DEG C, and the catalyst has strong anti-sulfur and anti-waterpoisoning performance and is suitable for treating NOx in diesel engine tail gas of automobiles and ships.

The invention relates to the field of a biological technology, in particular to a method for extracting amino acids from giant salamanders. The method comprises the following steps of (1) performing sterilization treatment; (2) performing hydrolization; (3) performing acidolysis; (4) performing neutralizing; (5) performing acidolysis for the second time; (6) performing neutralizing for the secondtime; (7) performing extraction; and (8) performing purification. Giant salamander skin and giant salamander muscle are mixed as raw materials for extracting the amino acids, giant salamander resources are sufficiently used, and through operation steps of sterilization treatment, hydrolization, acidolysis, neutralizing, acidolysis for the second time, neutralizing for the second time, extraction and purification, the extraction rate of amino acids in the giant salamander is effectively increased. Determination proves that the extraction rate of the amino acids is 82% or above, the purity is ashigh as 97% or above, requirements for the content and the quality of the amino acids in the market at current are effectively met, and the market application value of the amino acids is increased.

The invention relates to a pyrrolopyrimidine ketone compound and a preparation method and application thereof, and belongs to the technical field of medicine. The pyrrolopyrimidine ketone compound having a structural feature of formula I, or a pharmaceutically acceptable salt thereof has a very good inhibition effect on DPP-IV, and almost no effect on activity of DPP-VIII and DPP-IX, can effectively control the blood glucose concentration of diabetic rats, and is safe and low in toxicity through the verification of pharmacological and toxicological tests. After being prepared into a medicine, the compound provided by the invention not only has an obvious efficacy but also has very small side effects, thus greatly improving the administration convenience and patient use compliance, therefore, the compound has obvious advantages compared with the same kind of medicine. The formula is shown in the specification.

The invention discloses a gene cloning method, which comprises the following steps: connecting linear carrier with the same DNA sequences on the adjacent end of double-chain and object gene piece; forming annular DNA molecule; obtaining conversing bacterium; sieving to produce correct gene clone; fitting for augmentation product for kinds of PCR enzyme.

The invention relates to a zwitterionic cross-linking agent, a zwitterionic polymer and a zwitterionic injectable hydrogel for preventing postoperative adhesion, and a preparation method of the cross-linking agent, the polymer and the hydrogel. The method comprises the following steps of: subjecting N-methyl diethanolamine to acylation and ring-opening addition so as to synthesize the zwitterioniccross-linking agent with double bonds at two ends; subjecting a zwitterionic compound monomer and a disulfide bond monomer to free radical polymerization and disulfide bond reduction reaction so as to obtain the zwitterionic polymer with a sulfhydryl group in a side chain; and then respectively dissolving the cross-linking agent and the polymer in a phosphate buffer solution, and performing 'thiol-ene' addition reaction to obtain the zwitterionic injectable hydrogel. The prepared zwitterionic cross-linking agent and the zwitterionic polymer have excellent anti-protein performance, and the corresponding zwitterionic injectable hydrogel formed by the zwitterionic cross-linking agent and the zwitterionic polymer has better biocompatibility and anti-cell adhesion, and can be used as an anti-adhesion material for preventing postoperative adhesion.

The present invention relates to the technical field of development of drugs for treating inflammatory diseases and in particular to an application of a dendropanax dentiger coumarin compound to the preparation of a drug for treating rheumatoid arthritis or rheumatic arthritis. The dendropanax dentiger coumarin compound has one of chemical structural formulae shown as follows. Proven by activity screening experiments, three coumarin compounds in dendropanax dentiger has an obvious effect on inhibiting nitric oxide released by MH7A cells induced by tumor necrosis factor alpha (TNF-alpha), and median inhibitory concentration (IC50) values are respectively 7.87+ / -0.7 mu M (formula I), 13.82+ / -1.1 mu M (formula II) and 39.88+ / -2.3 mu M (formula III). The application provides a new research direction for the development of a drug for clinically treating rheumatoid arthritis and rheumatic arthritis.

The invention provides an application of an icarisid I type compound of formula I (shown in the specification) for preparing an IDO inhibitor. (The formula I is described in the specification). By study from the cellular level, the icarisid I can cause death of liver-cancer cells under the condition of existence of T cells, and proved from Western blot experiment, the icarisid I can regulate expression of main apoptosis protein in an IFN-gamma mediated apoptosis pathway in the liver-cancer cells under different concentrations. Results show that protein expression verifies the regulating effectof IFN-gamma, epimedium hormone can increase secretion of INF-gamma and enhance the own immunity of a human body. Further proved, the icarisid I can inhibit the activity of IDO obviously. In GAPDH antibody and IDO1 experiments, icarisid I can inhibit the activity of the IDO1 obviously and has no influence on the activity of the GAPDH antibody.

The invention relates to a hybrid pyrimido ketone DPP-IV inhibitor shown as a formula I as well as salts, a preparation method, compounds and application thereof in the prevention or treatment of diseases that benefit from the DPP-IV inhibitor. A preparation process of the DPP-IV inhibitor is simple, easily-obtained in raw materials and suitable for industrial large-scale production; and in-vitro and in-vivo experiments verify that the DPP-IV inhibitor has very good selective inhibition effect to DPP-IV, nearly has no influence on activities of DPP-VIII and DPP-IX at the same time of effectively inhibiting the DPP-IV activity, lower toxicity after prepared medicine development, stronger effect and longer acting time compared with the effect of a medicine Alogliptin with the same mechanism and shows excellent effects of reducing the blood sugar and increasing the insulin sensitivity. The formula I is shown as follows.

The invention relates to a compound shown in a formula I or a salt, a preparation and a composition thereof and application of the compound serving as a dipeptidyl peptidase-IV (DPP-IV) inhibitor to the prevention or treatment of diseases which benefit from DPP-IV inhibition. The compound has a simple preparation process, is readily available in raw materials and is suitable for large-scale industrial production; and in-vitro experiments verify that the compound has a good selective inhibition effect on the DPP-IV, and influences the activity of DPP-VIII and DPP-IX scarcely while the activity of the DPP-IV is inhibited effectively, so after the compound is developed to form medicaments, the toxicity is far lower than that of a control medicament, and the compound has prominent advantages.

The invention relates to the field of medicines, and particularly relates to an application of notoginsenoside R1. Experiments prove that NTR1 can be used for improving the cognition, learning and memory capabilities of an APP / PS1 transgenic AD mouse, restoring the intracerebral ChAT level of the mouse, reducing the intracerebral malondialdehyde level, and improving the mitochondrial function of the AD mouse by improving the CcO activity. In addition, the NTR1 also can be used for increasing the IDE level so as to promote degradation of A beta and inhibit the accumulation of the A beta. Therefore, the invention further provides the application of the notoginsenoside R1 to preparation of a medicament for treating an alzheimer disease. Moreover, experiments prove that the notoginsenoside R1 causes no influences to cell viability within a concentration range of 0-500 micromoles, so the notoginsenoside R1 is proved to be safe in medication.